Today, recombinant soluble ACE2 is being reconsidered for its potential use as an alternative treatment strategy for SARS-CoV-2-infected patients, and several research groups have verified the blocking effect of recombinant soluble ACE2 on the early infection of SARS-CoV-2 in preclinical tests such as human engineered organs, which is expected to promote the next clinical progress of rsACE2 (9)., focusing on the degree of improvement in pulmonary and renal symptoms and the efficacy and safety of the drug. The gene discussed is ACE2; the disease is infection.